These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

505 related items for PubMed ID: 24680648

  • 1. Menopausal hormone treatment cardiovascular disease: another look at an unresolved conundrum.
    Harman SM.
    Fertil Steril; 2014 Apr; 101(4):887-97. PubMed ID: 24680648
    [Abstract] [Full Text] [Related]

  • 2. Hormone replacement therapy and cardioprotection: what is good and what is bad for the cardiovascular system?
    Rosano GM, Vitale C, Fini M.
    Ann N Y Acad Sci; 2006 Dec; 1092():341-8. PubMed ID: 17308159
    [Abstract] [Full Text] [Related]

  • 3. Hormone replacement therapy in the post-Women's Health Initiative era. Report a a meeting held in Funchal, Madeira, February 24-25, 2003.
    Burger H.
    Climacteric; 2003 May; 6 Suppl 1():11-36. PubMed ID: 12945798
    [Abstract] [Full Text] [Related]

  • 4. Hormone therapy in menopause: An update on cardiovascular disease considerations.
    Hale GE, Shufelt CL.
    Trends Cardiovasc Med; 2015 Aug; 25(6):540-9. PubMed ID: 26270318
    [Abstract] [Full Text] [Related]

  • 5. What the Women's Health Initiative has taught us about menopausal hormone therapy.
    Chester RC, Kling JM, Manson JE.
    Clin Cardiol; 2018 Feb; 41(2):247-252. PubMed ID: 29493798
    [Abstract] [Full Text] [Related]

  • 6. Is the estrogen controversy over? Deconstructing the Women's Health Initiative study: a critical evaluation of the evidence.
    Harman SM, Naftolin F, Brinton EA, Judelson DR.
    Ann N Y Acad Sci; 2005 Jun; 1052():43-56. PubMed ID: 16024750
    [Abstract] [Full Text] [Related]

  • 7. The Women's Health Initiative could not have detected cardioprotective effects of starting hormone therapy during the menopausal transition.
    Naftolin F, Taylor HS, Karas R, Brinton E, Newman I, Clarkson TB, Mendelsohn M, Lobo RA, Judelson DR, Nachtigall LE, Heward CB, Hecht H, Jaff MR, Harman SM, Women's Health Initiative.
    Fertil Steril; 2004 Jun; 81(6):1498-501. PubMed ID: 15193467
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Changes of the prescription of hormone therapy in menopausal women: an observational study in Taiwan.
    Huang WF, Tsai YW, Hsiao FY, Liu WC.
    BMC Public Health; 2007 Apr 17; 7():56. PubMed ID: 17439639
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Recent epidemiological evidence relevant to the clinical management of the menopause.
    Shapiro S.
    Climacteric; 2007 Oct 17; 10 Suppl 2():2-15. PubMed ID: 17882666
    [Abstract] [Full Text] [Related]

  • 14. What can we learn from design faults in the Women's Health Initiative randomized clinical trial?
    Tan O, Harman SM, Naftolin F.
    Bull NYU Hosp Jt Dis; 2009 Oct 17; 67(2):226-9. PubMed ID: 19583558
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Implications of recent clinical trials of postmenopausal hormone therapy for management of cardiovascular disease.
    Rossouw JE.
    Ann N Y Acad Sci; 2006 Nov 17; 1089():444-53. PubMed ID: 17261787
    [Abstract] [Full Text] [Related]

  • 20. Discontinuation rates of menopausal hormone therapy among postmenopausal women in the post-WHI study era.
    Kyvernitakis I, Kostev K, Hars O, Albert US, Hadji P.
    Climacteric; 2015 Oct 17; 18(5):737-42. PubMed ID: 25845443
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.